The Urokinase Receptor (uPAR) as a “Trojan Horse” in Targeted Cancer Therapy: Challenges and Opportunities

SIMPLE SUMMARY: Discovered more than three decades ago, the urokinase-type plasminogen activator receptor (uPAR) has now firmly established itself as a versatile molecular target holding promise for the treatment of aggressive malignancies. The copious abundance of uPAR in virtually all human cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Metrangolo, Virginia, Ploug, Michael, Engelholm, Lars H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582577/
https://www.ncbi.nlm.nih.gov/pubmed/34771541
http://dx.doi.org/10.3390/cancers13215376

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582577/
https://www.ncbi.nlm.nih.gov/pubmed/34771541
http://dx.doi.org/10.3390/cancers13215376

Ejemplares similares